GJUN yields 5.07% · MRK yields 3.25%● Live data
📍 MRK pulled ahead of the other in Year 2
Combined, GJUN + MRK cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GJUN + MRK for your $10,000?
The investment objective of the FT Vest U.S. Equity Moderate Buffer ETF - June ("the Fund") is to seek to provide investors with returns (before fees and expenses) that match the price return of the SPDR S&P 500 ETF Trust (the "Underlying ETF"), up to a predetermined upside cap of 12.37% while providing a buffer (before fees and expenses) against the first 15% of Underlying ETF losses, over the period from June 23, 2025 to June 18, 2026.
Full GJUN Calculator →Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.
Full MRK Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.